DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate
insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 …

Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4
inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases …

Introduction: DPP-4 inhibitors are a class of compounds used for the treatment of type 2
diabetes. The drugs inhibit the degradation of GLP-1, thus amplifying the incretin effect. They …

Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2
diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive …

Although being a primary objective in the management of type 2 diabetes, optimal glycaemic
control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a …

Achieving and maintaining recommended glycemic targets without causing adverse e ffects,
including hypoglycemia, is challenging, especially in older patients with type 2 diabetes …

Summary The dipeptidyl peptidase 4 (DPP‐4) inhibitors enhance the body's own ability to
control blood glucose by increasing the active levels of incretin hormones in the body. Their …

In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates
the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent …

ABSTRACT Background: Glucagon-like peptide-1 (GLP‑1) and glucose-dependent
insulinotropic polypeptide (GIP) are hormones secreted by the enteroendocrine cells of the …

There is no consensus on the selection of specific drug therapies when metformin fails in
Type 2 diabetes (T2D). This meta-analysis was performed to determine the efficacy and …